By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Recordati S.p.A 

Via M. Civitali, 1

Milan    20148  Italy
Phone: 39-02-487871 Fax: 39-02-40073747


SEARCH JOBS


Industry
Pharmaceutical


Collaborations

Forest  Licensing agreement for the development of lercanidipine, a long-acting dihydropyridine calcium channel blocker for the treatment of hypertension.

Digital Gene Technologies  Atherosclerosis





Company News
Recordati: Preliminary 2016 Results Confirm Continued Growth Of Revenues And Profitability. New Three Year Business Plan Presented 2/9/2017 8:21:28 AM
Recordati To Meet With The Financial Community And Specialized Press In Milan 2/1/2017 7:41:46 AM
Recordati Announces Marketing Approval For Cystadrops 1/27/2017 7:53:51 AM
Apricus Biosciences (APRI) Announces The Launch Of Vitaros In The Czech Republic And Slovakia By Recordati 9/21/2016 9:19:03 AM
Apricus Biosciences (APRI) Announces The Launch Of Its Novel Topical Treatment For Erectile Dysfunction In Portugal, Ireland And Poland By Recordati 9/6/2016 8:07:03 AM
Recordati CEO Dies; Drug Giant Urgently Names New CEO 8/16/2016 9:57:46 AM
Apricus Biosciences (APRI) Announces The Launch Of Its Novel Topical Treatment For Erectile Dysfunction In Spain By Recordati S.p.A 5/6/2015 7:37:10 AM
Recordati S.p.A Finalizes The Second Tranche Of Its Acquisition Of Opalia Pharma In Tunisia 5/27/2014 9:37:15 AM
Prasco Laboratories Announces Authorized Generic Agreement With Recordati S.p.A 5/22/2014 9:35:51 AM
Recordati S.p.A: Sales Growth And Significant Margin Improvement In The First Quarter 2014 5/6/2014 9:13:51 AM
12345678910...
//-->